- Home
- Publications
- Publication Search
- Publication Details
Title
Do RANKL inhibitors (denosumab) affect inflammation and immunity?
Authors
Keywords
-
Journal
OSTEOPOROSIS INTERNATIONAL
Volume 22, Issue 2, Pages 435-446
Publisher
Springer Nature
Online
2010-06-22
DOI
10.1007/s00198-010-1326-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epidermal Receptor Activator of NF- B Ligand Controls Langerhans Cells Numbers and Proliferation
- (2014) J.-B. O. Barbaroux et al. JOURNAL OF IMMUNOLOGY
- The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse
- (2009) Rodrigo Fernandez-Valdivia et al. DEVELOPMENTAL BIOLOGY
- 20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
- (2009) D. Henry et al. EJC SUPPLEMENTS
- 2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study
- (2009) A. Stopeck et al. EJC SUPPLEMENTS
- One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength*
- (2009) Michael S Ominsky et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
- (2009) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies
- (2009) Marina Stolina et al. ARTHRITIS RESEARCH & THERAPY
- Human Osteoclast-Poor Osteopetrosis with Hypogammaglobulinemia due to TNFRSF11A (RANK) Mutations
- (2008) Matteo M. Guerrini et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
- (2008) J S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial
- (2008) Stanley B. Cohen et al. ARTHRITIS AND RHEUMATISM
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
- (2008) Paul D. Miller et al. BONE
- The BLyS Family: Toward a Molecular Understanding of B Cell Homeostasis
- (2008) John F. Treml et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
- (2008) Ann E. Kearns et al. ENDOCRINE REVIEWS
- Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL*
- (2008) Paul J Kostenuik et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
- (2008) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
- (2008) Georgiana K. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More